BeyondSpring, Inc..
BYSI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
BeyondSpring, Inc. is a global biopharmaceutical company focused on the development of innovative cancer therapies. Their lead asset, Plinabulin, is a selective immunomodulating microtubule-binding agent (SIMBA). It is being developed for the prevention of chemotherapy-induced neutropenia (CIN) and ...Show More
Better Health for All
0
No specific, concrete data points were found in the provided articles to assess BeyondSpring, Inc. against the 'Better Health for All' ethical value. The articles contain general statements about the company's mission to provide transformative medicine and its adherence to clinical trial guidelines.
1
but lack quantifiable evidence regarding the net health effect of its products, safety records (e.g., adverse event rates), pricing accessibility, investment percentages in health innovation or prevention, or the scale and impact of any health equity programs. Information about the founder's past research and patents does not provide current company-wide metrics for the specified KPIs.
Fair Money & Economic Opportunity
0
No evidence available to assess BeyondSpring, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess BeyondSpring, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
The provided article explicitly states that quantitative data specific to BeyondSpring, Inc. regarding fair trade and ethical sourcing is not available in the excerpt.
1
No information was found for any of the specified KPIs, including fair trade certifications, audit frequency, forced/child labor incidents, traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend.
2
Honest & Fair Business
-40
The company has a whistleblower policy in place, providing contact information (email and phone number) for reporting.
1
However, the provided evidence does not include information regarding independent investigation processes, training, or the effectiveness of the policy.
Kind to Animals
-40
The company conducts animal testing as part of its drug development process, as explicitly stated in multiple articles.
1
However, no formal policy regarding animal testing, its scope, or enforcement is provided in the evidence.
2
The absence of any stated policy, combined with the confirmation of animal testing, indicates a lack of transparency and commitment to animal welfare in this area.
No War, No Weapons
0
No evidence was found in the provided articles regarding BeyondSpring, Inc.'s involvement in arms manufacturing, military contracts, or dual-use technologies. The articles do not provide specific data points for any of the 'No War, No Weapons' KPIs for BYSI.US, including revenue from arms contracts, dual-use technology R&D, or sales to embargoed regimes. Information about other companies mentioned in the articles could not be directly attributed to BYSI.US.
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data points for any of the Planet-Friendly Business KPIs for BeyondSpring, Inc. While some articles mention sustainability initiatives, budgets, or reductions in energy/water/waste, they do not provide the necessary baseline figures, percentages, or ratios required by the rubric's quantitative thresholds. For example, energy consumption is provided in kWh, but not converted to tCO₂e for emissions.
1
Water usage is in gallons, but not per revenue unit.
2
Waste reduction is mentioned, but not a diversion rate.
3
Any data explicitly tied to 'Signet Jewelers (BYSI.US)' was excluded as the company description is for 'BeyondSpring, Inc.' despite sharing the ticker. Therefore, no KPIs can be scored based on the available evidence.
Respect for Cultures & Communities
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. The articles mention general commitments to environmental safety and minimizing environmental impact, as well as supporting people through non-profit fundraising and community services, but do not provide specific data points on formal partnerships with community groups, reinvestment in local development, cultural appropriation incidents, cultural impact protocols, local employment ratios, community grievance mechanisms, or cultural preservation investments.
1
Safe & Smart Tech
0
BeyondSpring's privacy policy, last updated September 1, 2020, states that users can request the removal or updates of their personal data via email.
1
The policy also indicates that data retention varies by purpose and mentions compliance with applicable laws.
2
No further specific details are provided regarding the extent of user control, data minimization practices, or the company's approach to regulatory compliance beyond these general statements.
Zero Waste & Sustainable Products
-60
BeyondSpring's subsidiary, SEED Therapeutics, has implemented two waste reduction initiatives: reusable glassware and recycling, which saves hundreds of pounds of plastic consumables quarterly, and miniaturizing drug screening efforts to cut waste.
1
The company and its contract manufacturing partners handle hazardous materials and waste, contracting with third parties for disposal.
2
Pharmaceutics International Inc. (Pii), a contract manufacturing partner, collects, labels, stores, arranges transportation, and properly disposes of universal hazardous waste, and employs a dedicated Environmental, Health and Safety Officer to ensure compliance.
3
BeyondSpring reported zero FDA enforcement actions for cGMP violations in 2022 and 2023.
4
The company seeks to collaborate with suppliers on innovative solutions and conducts qualification audits every two years on key suppliers to ensure compliance with protocols and contractual obligations.
5
No information is provided on programs to educate customers on proper disposal or recycling of products.
6